Evidence map›Paper›PMID 28242813›Full record

ArticleMolecular cancer research : MCR2017

Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.

Yozo Mitsui, Hiroaki Shiina, Taku Kato, Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Mitsuho Imai-Sumida, Priyanka Kulkarni, Pritha Dasgupta, Ryan Kenji Wong and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Yozo MitsuiDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan. mitsui@med.shimane-u.ac.jp Yuichiro.tanaka@ucsf.edu.
Hiroaki ShiinaDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Taku KatoDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Shigekatsu MaekawaDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Yutaka HashimotoDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Marisa ShiinaDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Mitsuho Imai-SumidaDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Priyanka KulkarniDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Pritha DasguptaDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Ryan Kenji WongDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Miho HirakiDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Naoko ArichiDepartment of Urology, Shimane University Faculty of Medicine, Izumo, Japan.
Shinichiro FukuharaDepartment of Urology, Osaka University Graduate School of Medicine, Suita, Japan.
Soichiro YamamuraDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Shahana MajidDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Sharanjot SainiDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Guoren DengDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Rajvir DahiyaDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California.
Koichi NakajimaDepartment of Urology, Toho University Faculty of Medicine, Tokyo, Japan.
Yuichiro TanakaDepartment of Urology, Veterans Affairs Medical Center, University of California, San Francisco, California. mitsui@med.shimane-u.ac.jp Yuichiro.tanaka@ucsf.edu.
San Francisco VA Medical Center · USShimane University · JPOsaka Gakuin University · JPToho University · JP

Funding

Molecular biomarkers for kidney cancer prognosis using non-coding RNAsR01CA199694 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI TANAKA, YUICHIRO · 2016 to 2020
$1.7M
BLRD VA I01 BX001123BLRD VA IK6 BX004473NCI NIH HHS R01 CA199694
6 · The paper itself

Abstract

The proteoglycan versican (VCAN) promotes tumor progression and enhances metastasis in several cancers; however, its role in clear cell renal cell carcinoma (ccRCC) remains unknown. Recent evidence suggests that VCAN is an important target of chromosomal

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Renal CellCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansKaplan-Meier EstimateKidneyMaleMiddle AgedBiomarkers, TumorNeoplasm ProteinsVersicans

Identifiers

PMID28242813
PMCPMC5890926
OpenAlexW2593094664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.